Evogene Ltd (EVGN)

[Rockurstocks]

7+ in sight!
$EVGN

[Fress]

Boomage!!!


hold your shares for life changing gains!!


you snooze you lose.


always early this will be $20.00 sooner than later.


this is a multibillion dollar market cap in the making cathie wood of ARKG ETF gets behinds winners..


major catalysts coming. I said it before and I will say it one more time buy all you can under $7.00



$100.00 stock potential Beam and edit went from the teens to $100.00 plus in a few month early trials. EVGN has blockbuster product coming early next year.



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders


$EVGN

[midastouch017]

she is going to run hard you can make book on that.

Spot on Fress!



6.51+0.56 (+9.41%)
As of 9:44AM EST. Market open.

New 52w/h

[Porterhouse10]

Excellent!

[Fress]

$7.00+ is in the cards today they just got more cash. Looking for ARKG to buy more soon watch and learn how this works. We just broke new highs and a 5 year high yesterday. This chart is just starting to launch


EVGN under the radar name gearing up for double digit dollars stock will be explosive soon.


70 million cash no debt.


a product commercially ready early next year that will take massive market share from Monsanto roundup a green friendly product.


How Much Money Does Monsanto Make From Roundup:

How much money does Monsanto make from Roundup? In 2015, the company made nearly $4.76 billion in sales and $1.9 billion in gross profits


EVGN is a leading computational biology gene editing AI company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.

EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf


Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders


$EVGN

[Fress]

Thanks just bought another 2k pre market she is going to run hard you can make book on that.

most undervalued gene editing platform AI computational application for green industrial & green agriculture including cannabis, fruits vegetables insects. And Biotech

Biotech subsidiary Biomica
Proof of concept, first-in-man study – Immuno-oncology program.
https://www.biomicamed.com/

EVGN Biomica microbiome-based therapeutics for immunology looks superior to Seres Therapeutics technology 2.5 billion company that went from 2.52-38.00


Seres therapeutics 2.4 billion market cap.
EVGN Biomica 200 million market cap.
EVGN has the superior tech look for a monster move into double digit dollars coming soon.

https://www.evogene.com/



EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf


Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders.



$EVGN

[midastouch017]

EVGN trades in TASE (Tel-Aviv Stock Exchange)
Sunday thru Thursday inclu.
Fri & Sat TASE closed.
Your quote is end trade Thursday in TASE.
The market leader is in the Naz due to the
average larger volume in any single day.

[Fress]

don't get scared or robbed for your shares.




I bought VTGN at .79 in December they did a raise at .92 it surged to $2.50 days later



company has many catalyst and hammers that are about to drop.



70 million in cash no debt commercial product hitting the market in 2022 massive revenue generator.



EVGN 52 week high & multi year high was made $6.49 yesterday.EVGN is going way higher!!


https://www.evogene.com/



get ready for liftoff!



double digits are coming.



green friendly revenue generating weed killer product next year to rival Monsanto which makes from Roundup? In 2015, the company made nearly $4.76 billion in sales and $1.9 billion in gross profits ...



only 40 million shares insiders & institutions like ARKG (cathie Wood & cantor fitzgerald own close to 50% the shares. high demand and low supply for these shares savvy investors are accumulating.


if you sold your shares call the police you have been robbed.


EVGN is a wealth creator at these levels. has 1000% ROI in the next year. Cathie Wood from ARK ETF owns it gene editing AI platform across many industries including biotech, agriculture & industrial


Cathie Wood ARKG ETF she picked Beam EDIT PACB gene editing stocks this one is going to exponentially grow and scale in share price and the EVGN has applications for biotech green agriculture and cannabis markets. This has 1000% upside potential by the end of the year.


EVGN is a leading computational biology gene editing AI company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.

EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf


Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders



$VTGN

[Fress]

EVGN up big in Israel
https://finance.yahoo.com/quote/EVGN.TA?p=EVGN.TA&.tsrc=fin-srch


Evogene Ltd. (EVGN.TA)
Tel Aviv - Tel Aviv Price. Currency in ILA


1,910.00+281.00 (+17.25%)


$EVGN

[midastouch017]

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-240249

Prospectus Supplement
(To prospectus dated August 10, 2020)


$28,000,000
Ordinary Shares

We have entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor, relating to our ordinary shares, par value NIS 0.02 per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, from time to time we may offer and sell ordinary shares having an aggregate gross sales price of up to $28,000,000 through Cantor, acting as sales agent, pursuant to this prospectus supplement and the accompanying prospectus.

Our ordinary shares are listed on the Nasdaq Stock Market, or Nasdaq, and the Tel Aviv Stock Exchange Ltd., or TASE, under the symbol “EVGN.” The last reported sale price of our ordinary shares on Nasdaq on January 12, 2021 was $5.22 per share.

Sales of our ordinary shares, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Subject to terms of the sales agreement, Cantor is not required to sell any specific number or dollar amounts of securities but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Cantor and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

Cantor will be entitled to compensation under the terms of the sales agreement at a fixed commission rate equal to 3% of the gross sales price per share sold. In connection with the sale of our ordinary shares on our behalf, Cantor will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Cantor will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contributions to Cantor against certain civil liabilities, including liabilities under the Securities Act. See “Plan of Distribution.”

Investing in our securities involves risks. See “Risk Factors” beginning on page S-6 of this prospectus supplement and in the documents we incorporate by reference into this prospectus supplement and the accompanying prospectus.

[Fress]

Great news we just got 28 million from Canter Fitzgerald.


broke a 52 week high and multi year today!!



EVGN gets the upper hand here can sell when they want too this reminds me of another company that I invested in recently & then the share price flew 175%+. a few weeks later.



this company now has plenty of cash & no debt.


I just bought another 5k shares after hours under $6.00


will buy 10-20k more shares tomorrow in increments between $6.00-$7.00 before it blast off into double digits and beyond.




Cathie Wood ARKG ETF & Cantor Fitzgerald owns EVGN and expects exponential growth and scaling on multiple fronts from this cutting edge gene editing AI technology protocol.


EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf


Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders.



$EVGN

[Instrumentalist]

$28m offering and the stock barely moved. People don't wanna sell their gold! https://ih.advfn.com/stock-market/NASDAQ/evogene-EVGN/stock-news/84098521/prospectus-filed-pursuant-to-rule-424b5-424b5

[swampboots]

EVGN pure unadulterated genius!!!

[Fress]

methodically adding up till $7.00


easy breezy $20.00+ can happen on a wide array updates on its gene editing AI platform that this company has in the EVGN
vast portfolio.


Cathie Wood ARKG owns EVGN and expects exponential growth and scaling on multiple fronts from this cutting edge technology protocol.


EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf


Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders.


$EVGN

[MWM]

$EVGN the breakout is now confirmed. $10 is next...

[midastouch017]

Security EVGN / Evogene, Ltd. (M4119S104)
Industry Agricultural Chemicals
Institutional Owners 25
Shares Outstanding 36,491,379 shares
Institutional Shares 13,096,154 - 35.89% (ex 13D/G)
Institutional Value $ 46,153 USD ($1000)
Related IL:EVGN / Evogene Ltd (20 owners)

https://fintel.io/so/us/evgn

[Fress]

Buy all you can under $7.00


This can surge at a moments notice. Lots of updates from the company coming on all fronts oncology, green agriculture, green industrial.


billion dollar plus market cap in the making. only 220 million market cap.


double digit dollars are coming you can make book on that!


under the radar gem just getting noticed now.


35 million shares only half are owned by insiders and institutions like cathie wood of ARKG ETF Crispr gene editing plays backed by ARKG is where you want to be invested.



https://www.evogene.com/



EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf


Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html


EVGN biz presentation:
https://www.evogene.com/wp-content/uploads/2020/09/Evogene_Investor_PPT_Sep-2020_FINAL.pdf


Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 220 million market cap 35 million shares 45% owned by institutions & insiders

$EVGN

[Instrumentalist]

Big move in 2020, expecting an even bigger break out this year! Huge volume influx late last year will mean a lot this year!

[MWM]

$EVGN start at 4:00

[Fress]

just warming up. Gene editing crispr


soon to be a parabolic runner as it continues its uptrend new 52 week highs today and on is way double digit dollars and beyond.



add to your stash and accumulate before it launches into a new orbit.


https://www.evogene.com/



EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf


Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders.



$EVGN

[MWM]

This is the Video that got me super interested and buying $EVGN

They use CRSPR tech in agriculture! $ARKG $CRSP $EDIT $SGMO $BEAM

https://www.linkedin.com/posts/evogene_agplenus-novel-mode-of-action-herbicide-activity-6744591094660657152-4qKy/

[midastouch017]

Day's Range 5.48 - 6.17
52 Week Range 0.75 - 6.17
Volume 1,210,976
Avg. Volume 1,422,504

$6.17 new 52w/h!

[Fress]

Float is way too small to handle the masses. Just the beginning.


my top pick for 2021



Cathie Wood discusses Genome gene editing stocks will become the next FANG stocks.

this stock can literally double or triple in a blink of an eye with its tiny float of 35 million half of the shares are owned by insiders and institutions like ARKG cathie woods genome ETF


if you have done your research this multiple hammers and catalyst this company is about to drop.


always early..


EVGN gene editing AI computational platform that Cathie Wood from ARKG is personally backing I have seen multiple gene editing stocks move 1000% in a matter of months that Cathie is invested in EVGN is next.


https://www.evogene.com/


EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf


Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders




$EVGN

[MWM]

$EVGN Blue Skies now!

[Rockurstocks]

Great start here! Grabbed more this am!
$EVGN

[MWM]

$EVGN Awesome! Over $6! $10 is coming quick imo!

[Porterhouse10]

Boom! Great call, nice DD!

[Fress]

EVGN 52 week high is coming up $6.00 then clear blue sky breakout...


https://www.evogene.com/



get ready for liftoff!



double digits are coming.



green friendly revenue generating weed killer product next year to rival Monsanto which makes from Roundup? In 2015, the company made nearly $4.76 billion in sales and $1.9 billion in gross profits ...



only 35 million shares insiders & institutions like ARKG (cathie Wood own close to 50% the shares. high demand and low supply for these shares savvy investors are accumulating.


if you sold your shares call the police you have been robbed.


EVGN is a wealth creator at these levels. has 1000% ROI in the next year. Cathie Wood from ARK ETF owns it gene editing AI platform across many industries including biotech, agriculture & industrial


Cathie Wood ARKG ETF she picked Beam EDIT PACB gene editing stocks this one is going to exponentially grow and scale in share price and the EVGN has applications for biotech green agriculture and cannabis markets. This has 1000% upside potential by the end of the year.


EVGN is a leading computational biology gene editing AI company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.

EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf


Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders





$EVGN

[midastouch017]

Make it a sticky post.
(I akready have one on)

[Porterhouse10]

Lookin good

[MWM]

Shark Bites: A Computational Predictive Biology Play
Upcoming catalyst are likely to put the stock on the radar screen of investors. $EVGN

By JAMES "REV SHARK" DEPORRE Jan 13, 2021 | 02:36 PM EST
Stocks quotes in this article: EVGN, ARKG
Evogene Ltd. (EVGN) is a small Israeli company that is using something called computational predictive biology to develop products in four different areas.

Computation Predictive Biology (CPB) is defined as "the development and application of data-analytical and theoretical methods, mathematical modeling and computational simulation techniques to the study of biological, ecological, behavioral, and social systems." More details can be found on Wikipedia.

EVGN believes that its CPB platform gives it a competitive edge that increases efficacy, reduces toxicity, cuts costs of development, and saves time. Forty of EVGN's 121 employees hold Ph.D.'s in a variety of disciplines.

EVGN has four subsidiaries, each with a different focus. The key areas of development are microbiome therapeutics, herbicides, pesticides, and medical cannabis.

This is obviously a highly complex business, but it is still quite small, and there are some upcoming catalysts that are likely to put the stock on the radar screen of investors.

One investor that already has discovered this stock is the Ark Genomic Revolution ETF (ARKG) , which was one of the top-performing ETFs in 2020. ARK is the largest investor in EVGN, and as of Jan. 12, 2021, held 4,583,323 shares of the 31.6 million that are outstanding.

The EVGN chart looks favorable as it consolidates in the $4.75-$5 area. I am looking to build this position further on any pullbacks.

[midastouch017]

Shark Bites: A Computational Predictive Biology Play
Upcoming catalyst are likely to put the stock on the radar screen of investors.

https://finance.yahoo.com/m/c5302400-16c8-3b81-8cf9-848a8858e044/shark-bites%3A-a-computational.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo

By JAMES "REV SHARK" DEPORRE Jan 13, 2021 | 02:36 PM EST
Stocks quotes in this article: EVGN, ARKG

Evogene Ltd. (EVGN) is a small Israeli company that is using something called computational predictive biology to develop products in four different areas.

Computation Predictive Biology (CPB) is defined as "the development and application of data-analytical and theoretical methods, mathematical modeling and computational simulation techniques to the study of biological, ecological, behavioral, and social systems." More details can be found on Wikipedia.

EVGN believes that its CPB platform gives it a competitive edge that increases efficacy, reduces toxicity, cuts costs of development, and saves time. Forty of EVGN's 121 employees hold Ph.D.'s in a variety of disciplines.

EVGN has four subsidiaries, each with a different focus. The key areas of development are microbiome therapeutics, herbicides, pesticides, and medical cannabis.

This is obviously a highly complex business, but it is still quite small, and there are some upcoming catalysts that are likely to put the stock on the radar screen of investors.

One investor that already has discovered this stock is the Ark Genomic Revolution ETF (ARKG) , which was one of the top-performing ETFs in 2020. ARK is the largest investor in EVGN, and as of Jan. 12, 2021, held 4,583,323 shares of the 31.6 million that are outstanding.

The EVGN chart looks favorable as it consolidates in the $4.75-$5 area. I am looking to build this position further on any pullbacks.

[Fress]

Float is way too small to handle the masses. Just the beginning.


Momentum building up. very high demand and very little supply only 35 million shares insiders & institutions like ARKG own over 45% of the shares.


All time high of $6.00 is pennies away then we go into uncharted territory.


this can double or triple in a blink of an eye. Quality name you want to hold for mind numbing gains.



always early..


Cathie Wood ARKG ETF picked Beam EDIT PACB gene editing stocks this one is going to exponentially grow and scale in share price and the applications for biotech green agriculture and weed markets. This has 1000% upside potential by the end of the year.


EVGN is a leading computational biology gene editing AI company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.

EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf


Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders


EVGN website:
https://www.evogene.com/

Boomage Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
https://mma-user-upload.mixedmartialarts.com/2020-09/tenor%20(8).gif


$EVGN

[MWM]

$EVGN added more here, Breakout coming...

[Porterhouse10]

Marching North

[Porterhouse10]

Let's Roll!

$EVGN
$OEG
$NNDM
$BFT

[MWM]

$EVGN I think it heads back to all time highs...

[Fress]

Don't let these clowns MM steal your shares shorts will be taken to cleaners here you can make book on that.


once you buy your shares lock and key them GTC sky high.


This has a green tech angle to it. do your DD first product hits the market in 2022 with massive revenue potential. A green friendly product that will take profits & market share from Monsanto Roundup product that had 6 billion in sales 2 billion in profits. Also a Cannabis angle. And a next level immunology platform all built on a next level gene editing & AI platform that Cathie Wood from ARKG ETF loves and sees this company scaling and exponential growth on multiple fronts



EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 195 million market cap 35 million shares 45% owned by institutions & insiders



https://www.evogene.com/


$EVGN

[Fress]

EVGN under the radar name gearing up for new highs, stock will be explosive soon.

EVGN showing solid strength, we should see a run to $6+ soon. then $10+ small float & owned by ARKG Cathie Wood

January 11th 2021 Global Agricultural Biotechnology Market Outlook 2020,Business Overview by 2027 Available in Latest Report Biomica, Evogene Ltd., Canonic ltd. , Bayer AG, Valent BioSciences LLC

The agricultural biotechnology business is anticipated to augment business germination in the projection period of 2020 to 2027 reckoning to USD 74.55 billion by 2027 expanding at an annual growth of 9.94% in the above-mentioned projection years.

This agricultural biotechnology market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on agricultural biotechnology market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Download Sample PDF Copy of Report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-agricultural-biotechnology-market

The major players covered in the agricultural biotechnology market report are KWS SAAT SE & Co. KGaA, ChemChina, Corteva., Limagrain, MITSUI & CO., LTD., AgPlenus ltd., Biomica, Evogene Ltd., Canonic ltd., Bayer AG, Valent BioSciences LLC, Nufarm Limited, Marrone Bio Innovations., Performance Plants Inc., ADAMA Ltd. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Focusing points in the report

Key trends in the market place
Major players and brands
Drivers and restrains of the market
Strategies of key players and product offerings
In-depth market segmentation
Global Agricultural Biotechnology Market Scope and Market Size

Agricultural biotechnology market is segmented on the basis of type, application, organism type, technology, and product. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of type, agricultural biotechnology market is segmented into molecular diagnostics, molecular markers, tissue culture, vaccines, genetic engineering, and others.
On the basis of application, the agricultural biotechnology market is bifurcated into transgenic crops, flower culturing, nutritional supplements, biofuels, antibiotic development, vaccine development and others.
On the basis of organism type, the agricultural biotechnology market is divided into plants, animals, microbes, and others.
On the basis of technology, the agricultural biotechnology market is fragmented into genome editing tools, ribonucleic acid interference [RNAi], biochips, deoxy ribonucleic acid [DNA] sequencing, and synthetic biology.
Based on the product, the agricultural biotechnology market is segregated into crop protection products, transgenic seeds, and synthetic biology-enables products. Crop protection products are further sub-categorized into biostimulants, and biopesticides. Transgenic seeds are further sub-segmented into soybean, fruits & vegetables, maize, cotton, and others.
Inquiry For Customize Report With Discount At https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-agricultural-biotechnology-market

Drivers:Global Agricultural Biotechnology Market

Escalated penetration of biotechnology, tissue culture, and molecular breeding and unique plant breeding is defining the success parameters of agricultural biotechnology market.

Agricultural biotechnology market is flourishing exponentially owing to the advancement of agriculture sciences this factor is driving the market growth.

Increment in the production and breeding of transgenic crop because of rising food demand from the consumer end is helping the agricultural biotechnology market to grow. Implementation of biotechnology tools to enhance the production value in terms of size, color, or yield of crops by modifying their traits is catering a potential market base for agricultural biotechnology business.

Adoption of biofuels and quality food demand which is free from pesticides or insecticides constituents is helping the agricultural biotechnology market a good volume of revenue and stock shares, in the developed and emerging pockets of farming countries. These certain values are driving the market growth of agricultural biotechnology market in the anticipated time phase of 2020 to 2027.

During the seven years period of business, agricultural biotechnology market is exposed to face some restraints and curbing factors such as dearth of adoption of such products by consumer base due to scarcity of knowledge, stringent regulations by government for modified crops. These parameters may impact the market growth. The upcoming technological advancements centrally focused upon producing quality crops and widening penetration of biotech-crop tactics in agriculture industry will help in to overcome the mentioned challenges.

Important Points Covered in Agricultural Biotechnology Market Report Are:

Study Coverage
Executive Summary
Breakdown Data by Manufacturers
Breakdown Data by Product
Breakdown Data by End User
Breakdown Data by Countries
Agricultural Biotechnology Market Opportunities, Challenges, Risks and Influences Factors Analysis
Company Profiles
Future Forecast (2020-2027)
Value Chain and Sales Channels Analysis
Research Findings and Conclusion
And More.
To know more about the studyhttps://www.databridgemarketresearch.com/reports/global-agricultural-biotechnology-market

Customization Available: Global Agricultural Biotechnology Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing [e-mail] . We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research
US: [phone]
UK: [phone]
Hong Kong: [phone]
Email: [e-mail]

https://ksusentinel.com/2021/01/11/global-agricultural-biotechnology-market-outlook-2020business-overview-by-2027-available-in-latest-reportbiomica-evogene-ltd-canonic-ltd-bayer-ag-valent-biosciences-llc/


EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 195 million market cap 35 million shares 45% owned by institutions & insiders



https://www.evogene.com/


$EVGN

[Fress]

January 11th 2021 Global Agricultural Biotechnology Market Outlook 2020,Business Overview by 2027 Available in Latest Report Biomica, Evogene Ltd., Canonic ltd. , Bayer AG, Valent BioSciences LLC

The agricultural biotechnology business is anticipated to augment business germination in the projection period of 2020 to 2027 reckoning to USD 74.55 billion by 2027 expanding at an annual growth of 9.94% in the above-mentioned projection years.

This agricultural biotechnology market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on agricultural biotechnology market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Download Sample PDF Copy of Report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-agricultural-biotechnology-market

The major players covered in the agricultural biotechnology market report are KWS SAAT SE & Co. KGaA, ChemChina, Corteva., Limagrain, MITSUI & CO., LTD., AgPlenus ltd., Biomica, Evogene Ltd., Canonic ltd., Bayer AG, Valent BioSciences LLC, Nufarm Limited, Marrone Bio Innovations., Performance Plants Inc., ADAMA Ltd. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Focusing points in the report

Key trends in the market place
Major players and brands
Drivers and restrains of the market
Strategies of key players and product offerings
In-depth market segmentation
Global Agricultural Biotechnology Market Scope and Market Size

Agricultural biotechnology market is segmented on the basis of type, application, organism type, technology, and product. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of type, agricultural biotechnology market is segmented into molecular diagnostics, molecular markers, tissue culture, vaccines, genetic engineering, and others.
On the basis of application, the agricultural biotechnology market is bifurcated into transgenic crops, flower culturing, nutritional supplements, biofuels, antibiotic development, vaccine development and others.
On the basis of organism type, the agricultural biotechnology market is divided into plants, animals, microbes, and others.
On the basis of technology, the agricultural biotechnology market is fragmented into genome editing tools, ribonucleic acid interference [RNAi], biochips, deoxy ribonucleic acid [DNA] sequencing, and synthetic biology.
Based on the product, the agricultural biotechnology market is segregated into crop protection products, transgenic seeds, and synthetic biology-enables products. Crop protection products are further sub-categorized into biostimulants, and biopesticides. Transgenic seeds are further sub-segmented into soybean, fruits & vegetables, maize, cotton, and others.
Inquiry For Customize Report With Discount At https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-agricultural-biotechnology-market

Drivers:Global Agricultural Biotechnology Market

Escalated penetration of biotechnology, tissue culture, and molecular breeding and unique plant breeding is defining the success parameters of agricultural biotechnology market.

Agricultural biotechnology market is flourishing exponentially owing to the advancement of agriculture sciences this factor is driving the market growth.

Increment in the production and breeding of transgenic crop because of rising food demand from the consumer end is helping the agricultural biotechnology market to grow. Implementation of biotechnology tools to enhance the production value in terms of size, color, or yield of crops by modifying their traits is catering a potential market base for agricultural biotechnology business.

Adoption of biofuels and quality food demand which is free from pesticides or insecticides constituents is helping the agricultural biotechnology market a good volume of revenue and stock shares, in the developed and emerging pockets of farming countries. These certain values are driving the market growth of agricultural biotechnology market in the anticipated time phase of 2020 to 2027.

During the seven years period of business, agricultural biotechnology market is exposed to face some restraints and curbing factors such as dearth of adoption of such products by consumer base due to scarcity of knowledge, stringent regulations by government for modified crops. These parameters may impact the market growth. The upcoming technological advancements centrally focused upon producing quality crops and widening penetration of biotech-crop tactics in agriculture industry will help in to overcome the mentioned challenges.

Important Points Covered in Agricultural Biotechnology Market Report Are:

Study Coverage
Executive Summary
Breakdown Data by Manufacturers
Breakdown Data by Product
Breakdown Data by End User
Breakdown Data by Countries
Agricultural Biotechnology Market Opportunities, Challenges, Risks and Influences Factors Analysis
Company Profiles
Future Forecast (2020-2027)
Value Chain and Sales Channels Analysis
Research Findings and Conclusion
And More.
To know more about the studyhttps://www.databridgemarketresearch.com/reports/global-agricultural-biotechnology-market

Customization Available: Global Agricultural Biotechnology Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing [e-mail] . We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research
US: [phone]
UK: [phone]
Hong Kong: [phone]
Email: [e-mail]

https://ksusentinel.com/2021/01/11/global-agricultural-biotechnology-market-outlook-2020business-overview-by-2027-available-in-latest-reportbiomica-evogene-ltd-canonic-ltd-bayer-ag-valent-biosciences-llc/


EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 195 million market cap 35 million shares 45% owned by institutions & insiders



https://www.evogene.com/


$EVGN

[Fress]

broke out of pennant.


one of my favorite stocks for 2021 mind numbing gains incoming...


this is just starting out.


clear blue sky breakout at $6.01


volume coming in. Should see a nice close.



consolidating well, stock is on a solid uptrend, gene editing AI computational platform Cathie Wood of ARK ETF owns EVGN. parabolic breakout is coming one of the most under the radar biotech gems in the market.



https://www.evogene.com/





EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf



Genome Stocks-Gene Editing.
$BEAM 5.4 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 195 million market cap 35 million shares 45% owned by institutions & insiders



https://tenor.com/view/lets-get-ready-to-announcer-gif-16017020


$EVGN

[MWM]

$EVGN starting to go, a breakout will be big...

[Porterhouse10]

Movin' on Up!

[Fress]

Genome Stocks the next FANG stocks according to Cathie Wood of ARKG.


EVGN Quiet name getting ready to go surge to all time new highs of $6.00 will go parabolic soon!


Cathie Wood from ARKG ETF is investing in companies that she sees has exponential growth & scaling EVGN is one of those companies in her ARKG ETF where she highlights Gene editing & AI will be future underpinnings of successful companies EVGN is built around next level bleeding cutting edge Gene editing and AI technology.

Cathie Wood on Gene editing stocks in her ETF & recent success stories.

Shares are scarce only 35 million 45%+ owned by Insiders & institutions

most of the shares are accounted for and are being held by savvy investors. double digit dollars coming sooner than later.


https://ksusentinel.com/2021/01/11/global-agricultural-biotechnology-market-outlook-2020business-overview-by-2027-available-in-latest-reportbiomica-evogene-ltd-canonic-ltd-bayer-ag-valent-biosciences-llc/

one of my top picks for 2021


Evogene’s CPB based solutions utilize comprehensive and integrated computational biology to provide life-science companies with tailor-made solutions for product discovery and development.
Microbes, small molecules and genetic genome elements can be applied to a wide variety of products within human health, agriculture and industrial applications.



EVGN WEBSITE:
https://www.evogene.com/



Gene editing AI platform applications for Biotech and agriculture.


Subsidiaries
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf

Biomica:
2021 Proof of concept, first-in-man study – Immuno-oncology program.


EVGN green gene editing product coming next year can be a blockbuster rivaling Monsantos Roundup which had billions yearly in sales from 2015.

What is an engineered green weed killer product worth in the market these days. coming to market in 2022

REHOVOT, Israel, Jan. 5, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, provided today a year-end update for the CRISPR-IL consortium, of which it is a member and Evogene's CSO, Dr. Eyal Emmanuel, serves as the consortium's Chairman. The CRISPR-IL consortium, which is supported by the Israeli Innovation Authority, was established to develop an artificial intelligence-based system, for CRISPR-CAS based workflows, "Go-Genome", providing end-to-end genome-editing, with improved precision and efficiency.
https://www.biospace.com/article/releases/evogene-provides-2020-year-end-update-for-crispr-il-consortium/

Kathy Woods of ARKG ETF has been buying EVGN
Kathy woods from ARKG all star stock picker best in class.

https://ark-funds.com/arkg

EVGN Biz Presentation
https://www.evogene.com/wp-content/uploads/2020/05/Evogene_Investor_PPT_May-2020-file.pdf

EVGN Subsidiary's which they own close to 100% in all
https://www.evogene.com/subsidiaries/
(1) Biomica Human Microbiome (gene editing)

Biomica Mission: Discovery and development of novel therapies for microbiome-related human disorders using computational predictive biology.

(2).Canonic
Medical Cannabis

Canonic Mission: Commercialization of precise & stable medical cannabis products for better therapeutic effects.

(3)
AgPlenus
Ag-Chemicals

AgPlenus Mission: Design next generation effective, sustainable and safer crop protection products by leveraging predictive biology.

(4) Lavie Bio
Ag Biologicals

Lavie Bio Mission: Improve food quality, sustainability and agricultural productivity through the introduction of microbiome based ag-biological products.


(5)Castera
Castor Oil Production

Castera Mission: Provide farmers with the most advanced Castor seeds & Ag-service solutions
--------------------------------------------------------------------

2022 commercial product of a (Green) weed killer that will take market share from Monsanto round up massive revenue potential next year!


Oncology pipeline to kill tumors..


EVGN is a wealth creator buy what you can afford and lock up your shares GTC sky high.


Genome Stocks-Gene Editing.
$BEAM 5.4 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders


Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
https://tenor.com/view/oh-yeah-dance-dancing-dances-party-gif-17442404


$EVGN

[Porterhouse10]

Crunchy crunch!

[MWM]

https://www.linkedin.com/posts/evogene_agplenus-novel-mode-of-action-herbicide-activity-6744591094660657152-4qKy

[Porterhouse10]

Little sideways action, consolidating a bit, 1 month chart is stout, ready for that green arrow headed North.

[Fress]

Boomage.

this is one of my favorite plays of 2021 add all you can before the stock launches into a new orbit of trading. $6.01 will be a blue sky breakout and a new all time high and then we go into the higher realms.

EVGN shares are very scarce insiders and institutions own almost 50% including Cathie Wood of ARKG ETF EVGN has 35 million shares total. Not that many shares left being gobbled up by smart money. Could see a BNGO move coming this way sooner than later.


EVGN double digit dollars coming.


I see the angles before they are being played.


always early.



EVGN wants to go parabolic seen so many stocks recently that didn't deserve a massive move up. EVGN does and will you can make book on that.


https://gifer.com/en/FTW



Genome Stocks-Gene Editing.
$BEAM 5 billion market cap
$EDIT 5.1 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 190 million market cap 35 million shares 45% owned by institutions & insiders


$EVGN

[Fress]

Added heavy at the open.



Cathie Wood of ARKG ETF owns EVGN & so do I. I'm buying more at the open before it breaks its all time high of $6.00 (blue sky breakout)


EVGN Biz Presentation
https://www.evogene.com/wp-content/uploads/2020/05/Evogene_Investor_PPT_May-2020-file.pdf

Evogene website:
https://www.evogene.com/


Genome Stocks-Gene Editing.
$BEAM 5 billion market cap
$EDIT 5.1 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders



$EVGN

[Porterhouse10]

Nets are cast if she wants to dip, Giddy Up!